$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000139047817000059 Filed on August 14, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.841M	$2.287M	$3.117M
YoY Change	23.23%	-35.12%	65.27%
% of Gross Profit
Research & Development	$1.827M	$2.184M	$6.175M
YoY Change	-70.41%	-59.88%	-14.2%
% of Gross Profit
Depreciation & Amortization	$230.0K	$26.00K	$0.00
YoY Change		333.33%	-100.0%
% of Gross Profit
Operating Expenses	$5.668M	$4.471M	$9.292M
YoY Change	-39.0%	-50.14%	2.3%
Operating Profit	-$4.911M	-$5.088M	-$9.292M
YoY Change	-47.15%	-43.26%	2.3%
Interest Expense	-$130.0K	-$130.0K	$13.87M
YoY Change	-100.94%	-96.72%	-408.91%
% of Operating Profit
Other Income/Expense, Net	-$5.796M	$0.00	$5.500M
YoY Change	-205.38%	-100.0%	6526.51%
Pretax Income	-$5.800M	-$4.600M	$8.280M
YoY Change	-170.05%	-64.89%	-161.38%
Income Tax	$117.0K
% Of Pretax Income
Net Earnings	-$5.913M	-$4.601M	$5.389M
YoY Change	-209.72%	-72.1%	-134.41%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.22	-$0.45	$0.59
Diluted Earnings Per Share	-$0.22	-$153.3M	$0.58
COMMON SHARES
Basic Shares Outstanding	37.42M shares	26.41M shares	9.102M shares
Diluted Shares Outstanding	37.42M shares		9.274M shares

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.10M	$27.60M	$19.60M
YoY Change	-7.65%	-20.46%	-56.73%
Cash & Equivalents	$18.07M	$18.10M	$19.59M
Short-Term Investments
Other Short-Term Assets	$14.20M	$14.40M	$25.70M
YoY Change	-44.75%	336.36%	888.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$32.29M	$42.05M	$45.28M
YoY Change	-28.69%	10.8%	-11.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$148.0K	$173.0K	$259.0K
YoY Change	-42.86%	-42.14%	-51.32%
Goodwill	$5.898M	$5.898M	$5.898M
YoY Change	0.0%	0.0%	-2.82%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$200.0K
YoY Change	-50.0%	0.0%	-97.56%
Total Long-Term Assets	$28.26M	$28.29M	$28.49M
YoY Change	-0.82%	-0.46%	-43.96%
TOTAL ASSETS
Total Short-Term Assets	$32.29M	$42.05M	$45.28M
Total Long-Term Assets	$28.26M	$28.29M	$28.49M
Total Assets	$60.55M	$70.33M	$73.78M
YoY Change	-17.92%	5.98%	-27.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$385.0K	$1.163M	$1.273M
YoY Change	-69.76%	14.13%	-45.08%
Accrued Expenses	$2.634M	$3.189M	$4.703M
YoY Change	-43.99%	-21.1%	-63.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$13.03M	$12.60M	$23.16M
YoY Change	-43.75%	236.82%	467.71%
Total Short-Term Liabilities	$34.54M	$36.27M	$47.22M
YoY Change	-26.86%	-14.1%	23.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$1.200M	$1.200M	$800.0K
YoY Change	50.0%	-80.95%	-88.41%
Total Long-Term Liabilities	$1.200M	$1.200M	$800.0K
YoY Change	50.0%	-80.95%	-68.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.54M	$36.27M	$47.22M
Total Long-Term Liabilities	$1.200M	$1.200M	$800.0K
Total Liabilities	$41.43M	$43.14M	$53.46M
YoY Change	-22.5%	-20.04%	1.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$323.1M
YoY Change
Common Stock	$346.0M	$345.7M	$314.7M
YoY Change	9.97%	10.75%	6.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.849M	$3.849M	$3.849M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	33.75K shares	675.0K shares	675.0K shares
Shareholders Equity	$19.13M	$27.19M	$20.32M
YoY Change
Total Liabilities & Shareholders Equity	$60.55M	$70.33M	$73.78M
YoY Change	-17.92%	5.98%	-27.65%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q2
OPERATING ACTIVITIES
Net Income	-$5.913M	-$4.601M	$5.389M
YoY Change	-209.72%	-72.1%	-134.41%
Depreciation, Depletion And Amortization	$230.0K	$26.00K	$0.00
YoY Change		333.33%	-100.0%
Cash From Operating Activities	-$3.050M	-$3.803M	-$11.49M
YoY Change	-73.46%	-71.22%	-3.12%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities		-$18.00K	$0.00
YoY Change		-98.3%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$15.52M
YoY Change		-23.11%
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	5.660M	$0.00	-3.630M
YoY Change	-255.92%	-100.0%	-183.83%
NET CHANGE
Cash From Operating Activities	-3.050M	-$3.803M	-11.49M
Cash From Investing Activities		-$18.00K	0.000
Cash From Financing Activities	5.660M	$0.00	-3.630M
Net Change In Cash	2.610M	-$3.803M	-15.12M
YoY Change	-117.26%	-176.38%	99.47%
FREE CASH FLOW
Cash From Operating Activities	-$3.050M	-$3.803M	-$11.49M
Capital Expenditures			$0.00
Free Cash Flow			-$11.49M
YoY Change			-6.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38405072	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
	dei	Trading Symbol TradingSymbol	GALE
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	10520000	USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	3707000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	5327000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-132000	USD
CY2016Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	5497000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	5327000	USD
CY2017Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-19000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-132000	USD
	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-3707000	USD
	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
	gale	Classof Warrantor Right Expired ClassofWarrantorRightExpired	13000	shares
	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	17000000	shares
CY2016	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P5Y
CY2017Q2	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	17000	shares
CY2016Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	1095000	USD
CY2017Q2	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	1227000	USD
CY2016Q4	gale	Contract Research Payable ContractResearchPayable	3088000	USD
CY2017Q2	gale	Contract Research Payable ContractResearchPayable	899000	USD
CY2017Q1	gale	Debt Instrument Covenant Liquidity Covenant DebtInstrumentCovenantLiquidityCovenant	13200000	USD
	gale	Debt Instrument Redemption Principal Amount Redeemed DebtInstrumentRedemptionPrincipalAmountRedeemed	4450000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	713000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y3M18D
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	0	USD
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	82000	USD
	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	0	USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	5590000	USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	10357000	USD
CY2016Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	1860000	USD
CY2017Q2	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	8510000	USD
CY2016Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	1860000	USD
CY2017Q2	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	8510000	USD
	gale	Fair Valueof Warrants Granted FairValueofWarrantsGranted	10357000	USD
CY2013Q2	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	38.60
CY2016Q4	gale	Gale401rights GALE401rights	9255000	USD
CY2017Q2	gale	Gale401rights GALE401rights	9255000	USD
CY2016Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2017Q2	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
	gale	Increase Decreasein Restricted Cashfor Financing Activities IncreaseDecreaseinRestrictedCashforFinancingActivities	0	USD
	gale	Increase Decreasein Restricted Cashfor Financing Activities IncreaseDecreaseinRestrictedCashforFinancingActivities	-4450000	USD
CY2016Q2	gale	Loss On Warrant Exchange LossOnWarrantExchange	-14392000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	-10520000	USD
CY2017Q2	gale	Loss On Warrant Exchange LossOnWarrantExchange	185000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	-3707000	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	233000	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	0	USD
CY2017Q2	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	466000	shares
	gale	Paymentof Cash Dividendsfor Covenanton Longterm Debt PaymentofCashDividendsforCovenantonLongtermDebt	24000000	USD
	gale	Paymentof Cash Dividendsfor Covenanton Longterm Debt PaymentofCashDividendsforCovenantonLongtermDebt	0	USD
	gale	Paymentson Disposalof Productive Assets PaymentsonDisposalofProductiveAssets	1050000	USD
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	324000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	0	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue		USD
CY2016Q4	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	100000	shares
CY2017Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	15000	shares
CY2013Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	9109	shares
CY2016Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	50000	shares
CY2016Q3	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	50000	shares
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	840000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	385000	USD
	us-gaap	Accretion Expense AccretionExpense	712000	USD
	us-gaap	Accretion Expense AccretionExpense	1078000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4292000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2634000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	229000	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	660000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	335436000	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	346026000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	356000	USD
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	425000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	10357000	USD
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1398000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2386000	shares
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20062000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20062000	shares
CY2016Q4	us-gaap	Assets Assets	65811000	USD
CY2017Q2	us-gaap	Assets Assets	60554000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	37499000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	32293000	USD
CY2016Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	813000	USD
CY2017Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	189000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29730000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19590000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18083000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18100000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18073000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10140000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-1050000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-7119000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-7488000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	79.40
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	4497466	shares
CY2016Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	17621702	USD
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	9292000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	18260000	USD
CY2017Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	79.40
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	49.40
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.60
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	30.20
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.60
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2570000	shares
CY2017Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	19557000	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20545000	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15224223	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37469274	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15190473	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37435524	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37435524	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	4000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	4814000	USD
CY2017Q2	us-gaap	Costs And Expenses CostsAndExpenses	4911000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	9999000	USD
CY2017Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	13171702	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1224672	USD
CY2017Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	146552	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5661000	USD
CY2017Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5661000	USD
CY2016Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	96000	USD
CY2017Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	96000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	65000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	51000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.58
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	975000	USD
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.29
CY2017Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.19
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	976000	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2016Q3	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2013Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7D
CY2016Q3	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y6M
CY2016	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y6M
CY2013Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7534
CY2016Q3	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	1.0663
CY2016	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7713
CY2013Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0120
CY2016Q3	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0135
CY2016	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0126
CY2016Q4	us-gaap	Goodwill Goodwill	5898000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	5898000	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	8278000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4824000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-7102000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-9384000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.91
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.13
CY2017Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.19
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.29
CY2016Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.90
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.13
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2889000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-6280000	USD
CY2017Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1302000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-10738000	USD
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.32
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.17
CY2017Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.03
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.34
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.32
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.17
CY2017Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.03
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.34
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-324000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-455000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-589000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1658000	USD
	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	839000	USD
	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	-3250000	USD
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-19900000	USD
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	350000	USD
	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	-21700000	USD
	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-141000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-147000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	25000	USD
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	138273	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	33864	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	463000	USD
CY2016Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-519000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-611000	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-687000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1660000	USD
	us-gaap	Interest Paid InterestPaid	606000	USD
	us-gaap	Interest Paid InterestPaid	102000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2017Q2	us-gaap	Interest Payable Current InterestPayableCurrent	99000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	37154000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	41427000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65811000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60554000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	30398000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	34539000	USD
CY2016Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	6059000	USD
CY2017Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	8685000	USD
CY2016Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	950000	USD
CY2017Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1300000	USD
CY2016Q2	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	-1800000	USD
	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	-1800000	USD
CY2017Q2	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	-1300000	USD
	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	-1300000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	16397000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	16397030	USD
CY2017Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	13025180	USD
CY2017Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	13025000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15623000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19979000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1056000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-25000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24707000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19964000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-17588000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12476000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	5389000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11104000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-8404000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20122000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9292000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18260000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4911000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9999000	USD
CY2016Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	17570000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	13436000	USD
CY2017Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2191000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	615000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	581000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	434000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	49000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	83000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20189000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15524000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	23641000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	78000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	261000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	199000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	148000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4779000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6175000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11618000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2044000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4406000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	18022000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	13597000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-302932000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-323054000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3117000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6642000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2867000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5593000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1278000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	425000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.763
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7563
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.3213
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1641
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0141
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0141
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0158
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0187
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	300000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	54.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	161000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	105000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.54
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.15
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	561000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	505000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	41.50
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.49
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	34.21
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.30
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M1D
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4913000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	82000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	15524000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	28657000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	19127000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28657000	USD
CY2017Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19127000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	33750	shares
CY2017Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	33750	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2017Q2	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2016Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	172137	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2017Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9273867	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9035173	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37421273	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31944243	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9101730	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9035173	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37421273	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31944243	shares

Files In Submission

Name	View Source	Status
0001390478-17-000059-index-headers.html	Edgar Link	pending
0001390478-17-000059-index.html	Edgar Link	pending
0001390478-17-000059.txt	Edgar Link	pending
0001390478-17-000059-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gale-20170630.xml	Edgar Link	completed
gale-20170630.xsd	Edgar Link	pending
gale-20170630x10q.htm	Edgar Link	pending
gale-20170630_cal.xml	Edgar Link	unprocessable
gale-20170630_def.xml	Edgar Link	unprocessable
gale-20170630_lab.xml	Edgar Link	unprocessable
gale-20170630_pre.xml	Edgar Link	unprocessable
gale20170630ex311.htm	Edgar Link	pending
gale20170630ex321.htm	Edgar Link	pending
q22017pipeline3.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2017 Q2 Form 10-Q Financial Statement

#000139047817000059 Filed on August 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2017 Q2 Form 10-Q Financial Statement

#000139047817000059 Filed on August 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls